Alvotech (ALVO) Aandelenoverzicht
Alvotech ontwikkelt en produceert via zijn dochterondernemingen biosimilaire geneesmiddelen voor patiënten over de hele wereld. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
ALVO Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alvotech Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$3.28 |
| 52 Week Hoogtepunt | US$9.94 |
| 52 Week Laag | US$2.94 |
| Bèta | 0.19 |
| 1 maand verandering | -20.77% |
| 3 maanden verandering | -9.39% |
| 1 Jaar Verandering | -61.50% |
| 3 jaar verandering | -66.05% |
| 5 jaar verandering | -66.73% |
| Verandering sinds IPO | -66.36% |
Recent nieuws en updates
Narratiefupdate • Jul 07
ALVO: Biosimilar Advances And Fresh Capital Raises Will Drive Future Upside
Analysts have revised their price target on Alvotech to $50.00, citing updated assumptions for revenue growth, profit margins, and a lower discount rate, which also leads to a reduced future P/E multiple in their models. What’s in the News for Alvotech Alvotech completed a series of capital raises, including a $125 million public offering and related transactions, with some analysts suggesting the stock may appear undervalued based on certain valuation measures, source: Alvotech stock offering coverage.
Narratiefupdate • Jun 23
ALVO: 2026 Guidance Balanced By Capital Raise And Regulatory Milestones
Analysts have adjusted their price target on Alvotech to $4.00. The updated view reflects slightly lower discount rate assumptions, a modestly higher revenue growth outlook and profit margin expectations, and a marginally lower future P/E multiple.Recent updates
Narratiefupdate • Jul 07
ALVO: Biosimilar Advances And Fresh Capital Raises Will Drive Future Upside
Analysts have revised their price target on Alvotech to $50.00, citing updated assumptions for revenue growth, profit margins, and a lower discount rate, which also leads to a reduced future P/E multiple in their models. What’s in the News for Alvotech Alvotech completed a series of capital raises, including a $125 million public offering and related transactions, with some analysts suggesting the stock may appear undervalued based on certain valuation measures, source: Alvotech stock offering coverage.Narratiefupdate • Jun 23
ALVO: 2026 Guidance Balanced By Capital Raise And Regulatory Milestones
Analysts have adjusted their price target on Alvotech to $4.00. The updated view reflects slightly lower discount rate assumptions, a modestly higher revenue growth outlook and profit margin expectations, and a marginally lower future P/E multiple.Seeking Alpha • Jun 08
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements
Summary Alvotech remains a commercial-stage biosimilar company with real revenue, partners, and a growing global footprint. I believe its main upside potential lies with the resubmission of AVT05 and AVT06 after its recent manufacturing delays in the US. ALVO’s valuation has been punished by regulatory setbacks in its manufacturing facilities. So if those concerns are resolved, the stock could quickly re-rate higher. However, there are also substantial risks related to its cash burn and runway until we see ALVO’s optimistic guidance materialize later this year. In my view, ALVO is a viable speculative "Buy" for investors who believe ALVO will ultimately satisfy the FDA’s CMC requirements. Read the full article on Seeking Alpha
Narratiefupdate • Jun 06
ALVO: FDA Resubmissions And 2026 Biosimilar Launch Plan Will Drive Upside
Analysts have trimmed their average price target on Alvotech to about $13.83 from $14.00, linking the change to updated views on future P/E assumptions, as well as adjusted expectations for revenue growth and profit margins. Analyst Commentary Recent Street research on Alvotech points to a mixed but focused view on the stock, with several firms adjusting price targets and updating their assumptions around P/E, revenue growth, and margins.Narratiefupdate • May 19
ALVO: 2026 Revenue Guidance And Pipeline Execution Will Drive Future Upside
Analysts have trimmed their price targets on Alvotech by $1 to $4. This reflects updated views on the company’s growth, profitability, discount rate, and future P/E assumptions.Narratiefupdate • Apr 29
ALVO: Biosimilar Pipeline And Patent Resolutions Will Support Future Upside
Analysts have reduced their average price target on Alvotech to $46.50, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent target cuts from several major banks. Analyst Commentary Recent Street research on Alvotech has centered on recalibrated price targets, with several banks updating their models for valuation drivers such as revenue growth assumptions, margin profiles and target P/E multiples.Narratiefupdate • Apr 15
ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential
Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.Narratiefupdate • Mar 31
ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside
Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS. Analyst Commentary Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.Narratiefupdate • Mar 17
ALVO: Biosimilar Pipeline Progress And Patent Resolutions Will Support Future Upside
Analysts have adjusted their price target for Alvotech to $64.74 per share. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E, while keeping the overall valuation level unchanged.Narratiefupdate • Mar 03
ALVO: Patent Resolution And Biosimilar Progress Will Support Future Upside
Analysts have updated their price target on Alvotech to $64.74 from $82.94, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Alvotech reported positive top line pharmacokinetic results for AVT80, its biosimilar candidate to Entyvio (vedolizumab), with the PK study meeting all primary endpoints in healthy adults, while biosimilarity has not yet been established by regulators.Narratiefupdate • Feb 17
ALVO: Biosimilar Progress And New Partnerships Will Shape Balanced Risk Outlook
Analysts have raised their price target on Alvotech to $5.00. This change is supported by slightly higher assumptions for revenue growth, profit margin and future P/E.Narratiefupdate • Feb 03
ALVO: Rebased UBS View And Patent Resolution Will Support Future Upside
Narrative Update on Alvotech Analysts have reduced their price expectations for Alvotech, with one recent update moving a target to US$10 from US$13, along with lower fair value estimates and more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Even with lower headline price targets, some bullish analysts still see room for upside in Alvotech.Narratiefupdate • Jan 20
ALVO: FDA Letters And Facility Remediation Will Guide Balanced Risk Outlook
Narrative Update on Alvotech The updated analyst price targets for Alvotech, which now cluster around US$8 to US$10 compared with prior views near US$13 to US$14, reflect analysts factoring in recent FDA complete response letters tied to inspection findings at the Reykjavik facility, while still recognizing the unchanged US$5 fair value estimate and broadly similar growth and margin assumptions in the model. Analyst Commentary Recent Street research on Alvotech points to a more cautious tone, with price targets now centered in the US$8 to US$10 range and at least one rating move to Hold after the complete response letter for AVT05 and related inspection findings at the Reykjavik facility.Narratiefupdate • Jan 05
ALVO: FDA Setbacks And Manufacturing Fixes Will Shape Balanced Risk Profile
Analysts have trimmed their fair value estimate for Alvotech from US$14.00 to US$5.00. This reflects lower price targets on the stock after recent FDA-related setbacks and manufacturing inspection concerns highlighted in recent research updates.Narratiefupdate • Dec 17
ALVO: Resolution Of FDA Inspection Issues Will Unlock Biosimilar Launch Upside
Analysts have reduced their average price target for Alvotech from about $26.40 to roughly $22.17 per share, citing FDA inspection related uncertainties around key biosimilar launches, as well as a series of recent target cuts and rating downgrades, as justification for a lower, though still constructive, valuation framework. Analyst Commentary Recent Street research reflects a more cautious stance on Alvotech, with several firms cutting price targets and one moving to the sidelines following regulatory setbacks tied to the company’s biosimilar pipeline.Narratiefupdate • Dec 03
ALVO: Regulatory Resolution Of Manufacturing Issues Will Restore Confidence And Future Upside
Analysts have trimmed their price targets on Alvotech, with cuts of roughly $3 to $6 per share. The reductions reflect increased perceived regulatory risk after recent FDA feedback on key biosimilar programs.Analyseartikel • Nov 20
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
Even though Alvotech ( NASDAQ:ALVO ) posted strong earnings recently, the stock hasn't reacted in a large way. We...Narratiefupdate • Nov 19
ALVO: Regulatory Progress Will Drive Renewed Confidence Amid Recent Downgrade
Alvotech's fair value price target saw a significant increase from $16.10 to $26.40, as analysts revised their outlook based on recent research reports and updated fundamentals. Analyst Commentary Recent analyst reports on Alvotech reflect a mix of optimism about the company's long-term potential and caution regarding recent regulatory and operational setbacks.Analyseartikel • Nov 09
Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues
Alvotech ( NASDAQ:ALVO ) shareholders that were waiting for something to happen have been dealt a blow with a 31% share...Analyseartikel • Nov 06
Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers
Market forces rained on the parade of Alvotech ( NASDAQ:ALVO ) shareholders today, when the analysts downgraded their...Narratiefupdate • Nov 05
ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks
Alvotech’s analyst price target has decreased from $17.50 to $16.10 per share. This change reflects analyst concerns over FDA feedback and the resulting downgrades after a recent inspection of the company’s manufacturing facility.Analyseartikel • May 25
Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%
Those holding Alvotech ( NASDAQ:ALVO ) shares would be relieved that the share price has rebounded 29% in the last...Analyseartikel • May 15
Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations
Unsurprisingly, Alvotech's ( NASDAQ:ALVO ) stock price was strong on the back of its healthy earnings report. However...Nieuw narratief • May 05
Biosimilar Pipeline And R&D Capability Will Open New Markets
Upcoming biosimilar launches and strategic manufacturing expansions might drive substantial revenue and margin growth, leveraging lost biologic patents.Analyseartikel • Apr 08
Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet
Unfortunately for some shareholders, the Alvotech ( NASDAQ:ALVO ) share price has dived 25% in the last thirty days...Seeking Alpha • Nov 21
Alvotech's Position In The Coming Biosimilar Gold Rush
Summary Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector. While facing risks like competition and partner dependency, Alvotech's strategic focus and operational scalability offer considerable growth potential for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Alvotech: Steady Progress Offers A Good Chance Of Upside
Summary Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million. With revenues of $600 million to $800 million promised in 2025, Alvotech stock stands a good chance of realising upside in the second half of 2024. Read the full article on Seeking AlphaAnalyseartikel • May 28
Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts
Celebrations may be in order for Alvotech ( NASDAQ:ALVO ) shareholders, with the analysts delivering a significant...Seeking Alpha • Apr 25
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
Summary Alvotech has received FDA approval for its biosimilar drugs Simlandi and Selarsdi, allowing the company to compete in the biosimilar market for Humira and Stelara. The company's stock price initially dropped after the FDA rejected Simlandi in 2023, but has since recovered. Alvotech's outlook for 2024 and 2025 is positive, with projected revenues of $300-$400 million and potential growth in the biosimilar market. Q1 2024 earnings will be announced on May 22 and have the potential to exceed Wall Street's expectations, in my view, setting the company on a long-term path to valuation growth, although significant headwinds remain in play. Read the full article on Seeking AlphaRendement voor aandeelhouders
| ALVO | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -9.1% | -2.4% | 0.7% |
| 1Y | -61.5% | 35.9% | 20.6% |
Rendement versus industrie: ALVO presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 35.9 % opleverde.
Rendement versus markt: ALVO presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 20.6 % opleverde.
Prijsvolatiliteit
| ALVO volatility | |
|---|---|
| ALVO Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van ALVO is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van ALVO is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2013 | 1,279 | Lisa Graver | www.alvotech.com |
Alvotech ontwikkelt en produceert via zijn dochterondernemingen biosimilar geneesmiddelen voor patiënten wereldwijd. Het bedrijf biedt biosimilar-producten voor de therapeutische gebieden auto-immuunziekten, oogaandoeningen, botaandoeningen en kanker. Het bedrijf levert AVT02, een adalimumab-formulering met hoge concentratie en laag volume, een biosimilar voor Humira voor de behandeling van verschillende ontstekingsaandoeningen, waaronder reumatoïde artritis, artritis psoriatica, de ziekte van Crohn, ankyloserende spondylitis ulceratieve colitis en andere indicaties; AVT04, een biosimilar voor Stelara voor de behandeling van verschillende ontstekingsaandoeningen, waaronder artritis psoriatica, de ziekte van Crohn, colitis ulcerosa, plaque psoriasis en andere indicaties; AVT06, een biosimilar van Eylea voor de behandeling van verschillende aandoeningen, zoals neovasculaire leeftijdsgebonden maculaire degeneratie, maculair oedeem na netvliesaderocclusie, diabetisch maculair oedeem en diabetische retinopathie; en AVT03, een biosimilar van Xgeva en Prolia voor de behandeling van het voorkomen van botbreuken, ruggenmergcompressie en de noodzaak van bestraling of botchirurgie bij patiënten met bepaalde soorten kanker, evenals het voorkomen van botverlies en het vergroten van de botmassa.
Alvotech Samenvatting
| ALVO fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.18b |
| Inkomsten(TTM) | -US$80.73m |
| Inkomsten(TTM) | US$562.04m |
2.1x
P/S-verhouding-14.5x
Koers/WinstverhoudingIs ALVO overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ALVO resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$562.04m |
| Kosten van inkomsten | US$216.20m |
| Brutowinst | US$345.85m |
| Overige uitgaven | US$426.58m |
| Inkomsten | -US$80.73m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Aug 19, 2026
| Winst per aandeel (EPS) | -0.23 |
| Brutomarge | 61.53% |
| Nettowinstmarge | -14.36% |
| Schuld/Eigen Vermogen Verhouding | -463.9% |
Hoe presteerde ALVO op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/10 16:50 |
| Aandelenkoers aan het einde van de dag | 2026/07/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Alvotech wordt gevolgd door 9 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Glen Santangelo | Barclays |
| Andrew Baum | Citigroup Inc |
| Peter Verdult | Citigroup Inc |